First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developin

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November 11, 2025, at 9:30 a.m. ETTD Cowen Immunology & Inflammation Summit; fireside chat on Thursday, November 13, 2025, at 2:00 p.m. ETJefferies Global Healthcare Conference in London; presentation on Thursday, November 20, 2025, at 12:00 p.m. GMT / 7:00 a.m. ET8th Annual Eve

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. "I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics," said Mr. Hoppenot. "With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of M

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million, before deducting placement agent fees and other expenses. The private placement includes participation from both new and existing investors including Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venr

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in CKD Well tolerated across all doses with an excellent safety profile and no serious adverse events observed Phase 2 trials in both PKU and CKD expected to initiate in 2026 Maze to hos

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately. "We're thrilled to welcome Misbah as Maze's Chief Financial Officer at such a pivotal time for the company. We are preparing for several key milestones, including data for MZE782 in phenylketonuria and chronic kidney disease in Q3 2025 and initial data from our Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease in Q1 2026," said Jason

MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling Patients with APOL1-Mediated Kidney Disease; Initial Data Expected in Q1 2026 Strong Balance Sheet with $264.5 Million in Cash and Cash Equivalents, Expected to Provide Cash Runway into H2 2027 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the second quarter

SOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that company management will participate in fireside chats during two upcoming investor conferences in July: H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025, at 2:30 p.m. ETBTIG Virtual Biotech Conference on Wednesday, July 30, 2025, at 9:20 a.m. ET Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 day

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET. A live webcast will be available in the Investors section of the company's website at www.MazeTx.com and archived for 60 days following the presentation. About Maze TherapeuticsMaze Therapeutics is a clinical-stage biopharmaceutica

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong Balance Sheet with $294.4 Million in Cash and Cash Equivalents, Expected to Provide Cash Runway into H2 2027 SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today reported financial results for the first quarter ended March 31, 2025, and reiterated upcoming milestones. "With two clinical pro

Wells Fargo initiated coverage of Maze Therapeutics with a rating of Overweight and set a new price target of $55.00

Raymond James initiated coverage of Maze Therapeutics with a rating of Outperform

BTIG Research initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $30.00

H.C. Wainwright initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $34.00

Wedbush initiated coverage of Maze Therapeutics with a rating of Outperform and set a new price target of $17.00

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

3 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

SCHEDULE 13G/A - Maze Therapeutics, Inc. (0001842295) (Subject)

SCHEDULE 13G/A - Maze Therapeutics, Inc. (0001842295) (Subject)

SCHEDULE 13G/A - Maze Therapeutics, Inc. (0001842295) (Subject)

10-Q - Maze Therapeutics, Inc. (0001842295) (Filer)

8-K - Maze Therapeutics, Inc. (0001842295) (Filer)

424B3 - Maze Therapeutics, Inc. (0001842295) (Filer)

S-1 - Maze Therapeutics, Inc. (0001842295) (Filer)

8-K - Maze Therapeutics, Inc. (0001842295) (Filer)

144 - Maze Therapeutics, Inc. (0001842295) (Subject)

8-K - Maze Therapeutics, Inc. (0001842295) (Filer)

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developin

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. "I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics," said Mr. Hoppenot. "With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of M

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in CKD Well tolerated across all doses with an excellent safety profile and no serious adverse events observed Phase 2 trials in both PKU and CKD expected to initiate in 2026 Maze to hos